Custom Search

News

Saturday 01 July 2006

Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody.

By: Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Morita H, Hashimoto T, Susuki K, Yuki N, Ikeda S.

J Clin Neurosci 2006 Jul;13(6):683-7

We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.

Use of this site is subject to the following terms of use